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ORIGINAL ARTICLE
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transcriptional regulatory circuit mediating LMO2 expression
in a subset of T-acute lymphoblastic leukaemia patients
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RB Lock4, P-S Jayaraman5, BJ Huntly1, JE Pimanda2 and B Go¨ttgens1
1Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; 2Lowy Cancer
Research Centre and The Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
3Institute for Research in Immunology and Cancer, Universite´ de Montre´al, Montre´al, Quebec, Canada; 4Children’s Cancer Institute
Australia, University of New South Wales, Sydney, New South Wales, Australia and 5Birmingham University Stem Cell Centre,
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The T-cell oncogene Lim-only 2 (LMO2) critically
inﬂuences both normal and malignant haematopoiesis.
LMO2 is not normally expressed in T cells, yet ectopic
expression is seen in the majority of T-acute lympho-
blastic leukaemia (T-ALL) patients with speciﬁc translo-
cations involving LMO2 in only a subset of these patients.
Ectopic lmo2 expression in thymocytes of transgenic mice
causes T-ALL, and retroviral vector integration into the
LMO2 locus was implicated in the development of clonal
T-cell disease in patients undergoing gene therapy. Using
array-based chromatin immunoprecipitation, we now
demonstrate that in contrast to B-acute lymphoblastic
leukaemia, human T-ALL samples largely use promoter
elements with little inﬂuence from distal enhancers. Active
LMO2 promoter elements in T-ALL included a previously
unrecognized third promoter, which we demonstrate to
be active in cell lines, primary T-ALL patients and transgenic
mice. The ETS factors ERG and FLI1 previously implicated
in lmo2-dependent mouse models of T-ALL bind to the novel
LMO2 promoter in human T-ALL samples, while in return
LMO2 binds to blood stem/progenitor enhancers in the FLI1
and ERG gene loci. Moreover, LMO2, ERG and FLI1 all
regulate the þ 1 enhancer of HHEX/PRH, which was
recently implicated as a key mediator of early progenitor
expansion in LMO2-driven T-ALL. Our data therefore
suggest that a self-sustaining triad of LMO2/ERG/FLI1
stabilizes the expression of important mediators of the
leukaemic phenotype such as HHEX/PRH.
Oncogene (2010) 29, 5796–5808; doi:10.1038/onc.2010.320;
published online 2 August 2010
Keywords: LMO2; leukaemia; transcriptional regula-
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Introduction
Lim-only 2 (LMO2), also known as TTG2 or RBTN2,
was originally reported as a T-cell oncogene where it
was recurrently rearranged by chromosomal transloca-
tion in T-cell malignancies (Boehm et al., 1991; Royer-
Pokora et al., 1991). LMO2 encodes a 156 amino-acid
transcriptional co-factor containing two LIM domain
zinc-ﬁngers (Kadrmas and Beckerle, 2004) that do not
bind to DNA directly, but rather participate in the
formation of multipartite DNA-binding complexes with
other transcription factors, such as LDB1, SCL/TAL1,
E2A and GATA1 or GATA2 (Osada et al., 1995;
Wadman et al., 1997; Valge-Archer et al., 1998).
Although translocations involving LMO2 are present
in o10% of T-acute lymphoblastic leukaemia (T-ALL)
patients, LMO2 is ectopically aberrantly expressed in
more than 60% of T-ALL samples (Rabbitts et al.,
1997; Raimondi, 2007). Ectopic expression of lmo2 in
thymocytes of transgenic mice has conﬁrmed a role in
the aetiology of T-ALL and the generation of T-ALL is
greatly accelerated if SCL and LMO2 are simulta-
neously overexpressed (Larson et al., 1995, 1996).
LMO2 therefore represents one of the major oncogenes
involved in the development of T-ALL.
Within the haematopoietic system, LMO2 is ex-
pressed at all levels of maturity with the exception of
mature T-lymphoid cells. LMO2 expression has been
shown to be critical for primitive haematopoiesis
(Warren et al., 1994; Yamada et al., 1998). Moreover,
lmo2 null embryonic stem cells fail to contribute to adult
haematopoiesis in chimeric mice, indicating that LMO2
is essential for the generation of blood stem cells.
The majority of T-ALL samples expressing LMO1/2
and SCL/LYL1 do not have rearrangements of
these genes (Asnaﬁ et al., 2004; Ferrando et al., 2004).
However, mechanisms mediating overexpression in
cytogenetically normal T-ALL remain unknown.
LMO2 overexpression is seen most consistently in the
more immature T-ALL phenotypes (van Grotel et al.,
2008), which have previously been associated with poor
treatment outcome (Crist and Pui, 1993; Garand and
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Bene, 1993). Importantly, ectopic LMO2 expression due
to transcriptional activation following retroviral vector
integration into the LMO2 locus has also been
implicated in the development of clonal T-cell prolifera-
tion and subsequent T-ALL in patients undergoing gene
therapy for X-linked severe combined immunodeﬁciency
(Hacein-Bey-Abina et al., 2003b, 2008; Howe et al.,
2008), and this has recently been recapitulated using
murine retroviral mutagenesis models (Dave et al.,
2009). Taken together, the evidence from T-ALL
patients, the transgenic mouse models and the inser-
tional mutagenesis observations suggest that aberrant
LMO2 expression in an immature haematopoietic cell
represents a ‘ﬁrst-hit’ to cause an accumulation of
early lymphoid precursors with subsequent progression
to T-ALL. Further evidence for this model has come
from a recent study wherein it was demonstrated that
CD2-driven lmo2 is sufﬁcient to permit the establish-
ment of the leukaemia-initiating cell within the thymus
many months before the development of leukaemia
(McCormack et al., 2010).
The regulation of LMO2 expression therefore has
implications for both haematopoiesis and leukaemogen-
esis and accordingly has been of interest for some time.
Studies of the regulation of LMO2 expression in normal
haematopoeisis have shown two alternative transcripts
(Royer-Pokora et al., 1995), originating from the
proximal and distal promoters, respectively, and that
the proximal promoter drives the majority of LMO2
expression in endothelial cells (Landry et al., 2005). In
addition, a cis-regulatory element has been identiﬁed in
the ﬁrst untranslated exon of LMO2, which contains a
PAR consensus-binding site (Crable and Anderson,
2003). Recently, further delineation of LMO2 regulatory
elements active in normal haematopoiesis (Landry et al.,
2005, 2009) has been reported but, thus far, the
molecular mechanisms responsible for LMO2 expres-
sion in leukaemic cells remain elusive, save for the recent
identiﬁcation of a cryptic chromosomal deletion in 4%
of paediatric T-ALL patients deleting a region immedi-
ately upstream of LMO2, which was hypothesized
to remove a putative negative regulatory element
(Hammond et al., 2005). Therefore, identiﬁcation of
upstream regulators of LMO2 in leukaemic cells may
permit the discovery of critical transcription factors that
characterize T-ALL transcriptional programmes and
may thus open up new avenues for the development of
future therapies.
Our interest was therefore to utilize chromatin
immunoprecipitation (ChIP) with antibodies to activat-
ing histone modiﬁcation marks in primary human
samples coupled with microarray technology to discover
regulatory sequences active in T-ALL. We have
identiﬁed that (i) a proposed novel third promoter and
both known promoters of LMO2 are active in T-ALL
and (ii) in contrast to B-acute lymphoblastic leukaemia
(B-ALL), that the overexpression in T-ALL was
directed from promoters with little inﬂuence by en-
hancer elements. We have also established that the
proposed novel promoter is functional in reporter assays
in cell lines and in F0 transgenic mice and that
transcripts originating at this promoter are present in
T-ALL cell lines, primary T-ALL patient material and
normal haematopoietic cells. We also identiﬁed FLI1
and ERG as likely transcriptional regulators of LMO2
in T-ALL and that LMO2 acts on FLI1 and ERG in a
parallel manner. In addition, we demonstrate that these
three factors bind to a powerful enhancer element in
HHEX/PRH, the ﬁrst time this has been demonstrated
in human malignancy. Together with the data suppor-
tive of FLI1, ERG and LMO2 co-regulation, we suggest
that these four transcription factors collaborate to form
a key regulatory subcircuit of the wider transcriptional
networks driving the development of T-ALL.
Results
A range of chromatin mark proﬁles are seen across
the LMO2 locus in normal endothelial and blood cells
To demonstrate the feasiblilty of generating ChIP-on-
chip proﬁles across the LMO2 locus in human normal
endothelial and blood cells and to show the range of
proﬁles that may be derived in normal cells, we
performed ChIP-on-chip analysis using antibodies to
the histone modiﬁcation marks H3K4Me3 and H3K9Ac
in placenta-derived endothelial cells and in peripheral
blood-derived CD34þ and T-cells (Figure 1). As
expected from our previous mouse studies (Landry
et al., 2005), the proximal promoter was the dominant
feature in endothelial cells and the locus was silent in T
cells with internal control provided by the inclusion of
the promoter of the neighbouring gene CAPRIN1.
Three peaks were noted by H3K4Me3 ChIP-on-chip in
LMO2 in peripheral blood-derived blood progenitors
(CD34þ cells): a peak each at the previously described
proximal and distal promoters, and a third peak
between these. In addition, a 50 H3K9Ac peak was seen
in the CD34þ cells, which corresponded to the 64 kb
element previously seen in mouse studies (Landry et al.,
2009) and shown to induce expression in haematopoietic
cells in fetal liver.
The distribution of active histone marks across the LMO2
locus is different in LMO2-expressing T-ALL and B-ALL
To investigate the underlying cause of LMO2 over-
expression in T-ALL, we next performed ChIP-on-chip
analysis in primary T-ALL and B-ALL samples pre-
viously banked at the Sydney Children’s Hospital and
passaged through NOD-severe combined immunodeﬁ-
ciency mice (Lock et al., 2002). In contrast to the silent
LMO2 locus in normal T-cells (Figure 1), there are
strong peaks of H3K4Me3 and H3K9Ac seen over the
previously described proximal promoter of LMO2 in the
three highly expressing T-ALL samples T-ALL 8, 16 and
27 with smaller peaks for the lowly expressing samples
T-ALL 29 and 30 (Figure 2, Supplementary Figure 1A).
Samples T-ALL 8 and 16 also showed an acetylation
peak over the previously described distal promoter.
In addition, there is a third peak of K4Me3 (strong in
T-ALL 27 and weaker in T-ALL 16, 29 and 30) at a
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position just upstream of exon 2. These ChiP-on-chip
ﬁndings were further corroborated by real-time PCR
analysis of ChIP material (Supplementary Figure 1B).
On review of transcript databases, it is seen that there
are transcripts beginning at this position in both human
and mouse with the database of transcriptional start
sites (http://dbtss.hgc.jp/) identifying transcripts starting
at this position in fetal liver (Supplementary Figure 2).
Moreover, multisequence alignment reveals near 100%
sequence conservation across mammals (Supplementary
Figures 3 and 4). Taken together, this evidence suggests
the presence of a previously unrecognized third promo-
ter of LMO2, which is active in T-ALL. Comparison of
the H3K4Me3 and H3K9Ac plots revealed that there is
just one solely H3K9Ac positive region upstream of
LMO2 (only seen in T-ALL 8) and one small region
downstream of LMO2 (seen in T-ALLs 8, 16, 27 and
29), suggesting that LMO2 expression in T-ALL is
largely driven by promoters with little additional
enhancer activity.
We have previously shown that mouse lmo2 expres-
sion depends on an array of distal regulatory elements
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Figure 1 H3K4Me3 and H3K9Ac ChIP-on-chip demonstrates multiple peaks over the LMO2 locus in human primary cells,
HUVECs, T cells and CD34þ cells. Shown at the top of the ﬁgure is a comparative genomics conservation plot generated using the
Vista genome browser. The location of the exons of LMO2 and FBX03 are shown with non-coding exons in blue and coding exons in
purple. Underneath are the results for ChIP-on-chip studies of placenta-derived endothelial as well as peripheral blood-derived
T-cell and blood progenitor cells using antibodies to histone modiﬁcations H3K4Me3 (thought speciﬁc for promoters) and H3K9Ac
(highlighting sequences with likely enhancer and/or promoter activity). The plot shows multiple peaks across the LMO2 locus.
Endothelial cells demonstrate an H3K4Me3 peak over the LMO2 proximal promoter; the locus is silent in T cells and peaks are evident
over both the LMO2 proximal and distal promoters and over a third peak between these over a presumed third promoter in peripheral
blood-derived blood progenitors (CD34þ cells). Internal control is provided by inclusion of the promoter of the neighbouring
gene, FBX03.
Novel LMO2 promoter in positive feedback loop in T-ALL
SH Oram et al
5798
Oncogene
spread over more than 100 kb of genomic sequence
(Landry et al., 2009). To verify that our failure to pick
up distal elements in the LMO2 H3K9Ac ChIP-on-chip
analysis was due to the particular mode of LMO2
control in these ectopically expressing cells rather than
fundamental differences between the control of human
and mouse LMO2 expression, we also studied the
human LMO2 locus by ChIP-on-chip in B-ALL
samples. In contrast to the T-ALL samples, we observed
considerably more distal H3K9Ac peaks in the B-ALL
samples upstream of LMO2 (Figure 3). Of note, the
smaller peaks in sample B-ALL 11 corresponded to
peaks seen in the other two samples consistent with the
notion that transcriptional control in B-ALL is more
complex involving both promoter and enhancer ele-
ments. The main peaks seen in the H3K9Ac plots
precisely correspond to regions previously identiﬁed to
be important for murine lmo2 expression (Landry et al.,
2009).
In summary, LMO2 expression in T-ALL appears to
be driven predominantly by promoter activation in
contrast with the promoter–enhancer cooperation seen
100%
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Figure 2 H3K4Me3 and H3K9Ac ChIP-on-chip demonstrates peaks largely restricted to promoters in the LMO2 locus in human
T-ALL samples. Shown at the top of the ﬁgure is a comparative genomics conservation plot generated in Vista genome browser as in
Figure 1. This is followed by ChIP-on-chip plots in xenograft T-ALLs, which demonstrate peaks over the two previously described
promoters of LMO2 and over the newly described third promoter. There are no prominent H3K9Ac-only peaks evident, supportive of
a promoter-predominant drive to transcription. LMO2 expression status is indicated.
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in B-ALL. Additionally, these experiments have sug-
gested the presence of a third previously undescribed
promoter of LMO2. From now forward this region will
be termed the putative intermediate promoter.
Additional evidence for the relevance of this promoter
became evident when we analysed recently deposited
data from ChIP sequencing human CD36-, CD19- and
CD34-positive cells subjected to ChIP for the promoter
mark H3K4Me3. Strong peaks were seen in the
presumed novel promoter region in erythroid cells and
CD34þ cells (Supplementary Figure 5). Furthermore,
real-time PCR analysis of ChIP with an antibody to
H3K4Me3 material from T-ALL cell lines and primary
samples demonstrated the presence of the promoter
speciﬁc mark on this new promoter not only in Lmo2-
expressing cell lines but also in a subset of primary
patient samples (Supplementary Figures 6A and B).
The putative intermediate promoter is active in T-ALL
cell lines
Having identiﬁed a possible third promoter of LMO2, we
next proceeded to validate this in experimental models.
We ﬁrst investigated the LMO2 expression status of a
panel of human T-ALL cell lines by real-time PCR. The
11p13 translocation status was ascertained using break-
apart FISH (Supplementary Figure 7) and conﬁrmed to
be in agreement with published data and reference
information in international cell banks. We were there-
fore able to identify three types of T-ALL cell lines with
respect to LMO2: (i) non-LMO2-expressing, (ii) LMO2-
expressing, not translocated and (iii) LMO2-expressing,
translocated. In Figure 4a, we present data conﬁrming
that the human T-ALL cell lines Jurkat and All-Sil do
not express LMO2. The cell lines Molt4, CCRFCEM,
Peer and Loucy express LMO2 but do not show evidence
of a translocation involving LMO2, whereas the cell lines
KOPTK1 and Karpas45 express LMO2 and each have
translocations involving LMO2 (Figure 4a, Supplemen-
tary Figures 6 and 7, Supplementary Table 1).
We next generated luciferase reporter constructs
containing the two known promoters and the putative
intermediate promoter (proximal promoter/LUC, inter-
mediate promoter/LUC, distal promoter/LUC). Stable
transfection assays demonstrated that activity of the three
promoters in the LMO2-non-expressing cell lines or
LMO2-expressing cell lines with a translocation involving
20 Kn
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Figure 3 H3K4Me3 and H3K9Ac ChIP-on-chip demonstrates peaks over promoters and enhancer elements in the LMO2 locus in
human B-ALL samples. Shown at the top of the ﬁgure is a comparative genomics conservation plot as in Figure 1. H3K4Me3 ChIP-
on-chip plots in xenograft B-ALLs demonstrate peaks over the two previously described promoters of LMO2 and over the newly
described third promoter. In contrast with the T-ALL samples, numerous H3K9Ac-only peaks are evident, supportive of promoter–
enhancer cooperation to drive transcription.
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LMO2 was no higher than background in all instances
with the exception of the proximal promoter, which
showed modest activity in Jurkat cells. By contrast, all
the promoters were signiﬁcantly more active than empty
vector (pGL2 basic) in LMO2-expressing cell lines
without a translocation with the putative intermediate
promoter displaying the highest activity (Figure 4b).
Activity of the three promoters in LMO2-expressing non-
translocated cell lines was conﬁrmed by ChIP-on-chip
using an antibody to the promoter-speciﬁc histone mark
H3K4Me3 in Molt4 (Figure 4c). Taken together, these
results allow us to draw the following conclusions:
(i) there is a third promoter of LMO2; (ii) T-ALL cell lines
represent suitable models in which to investigate aspects
of its function further; (iii) the transfection data are
consistent with the ability of promoters to respond to the
T-ALL transcriptional environment in non-translocated,
LMO2-expressing T-ALL.
Transcripts derived from the putative intermediate
promoter are apparent in T-ALL cell lines and T-ALL
primary samples
To quantify the contribution of transcripts starting at
each of the three LMO2 promoters, PCR primers were
designed to permit ampliﬁcation of regions unique to the
distal and intermediate promoters and a region shared
by all three transcripts (total LMO2), thereby permitting
calculation of the contribution of transcripts sourced at
the proximal promoter using a subtractive approach
(Figure 5a). Transcripts beginning at each of the three
promoters were quantiﬁed against a DNA template
by real-time PCR and standardized for housekeeping
gene expression (Figure 5b). A selection of expression
patterns were seen in T-ALL cell lines. Lack of LMO2
expression was conﬁrmed in All-Sill and Jurkat and high
total LMO2 expression with low or no discernable
transcripts from the intermediate or distal promoters in
the 11q13-translocated cell lines Karpas45 and KOPT-
K1. Transcripts starting at each promoter were evident
in the untranslocated LMO2-expressing cell lines Molt4,
CCRFCEM and Peer, whereas Loucy cells only showed
activity for the distal and proximal promoters. Inter-
mediate promoter transcripts are also seen as a variable
proportion of all transcripts in primary T-ALL samples
(Figure 5c) with the highest levels of intermediate
promoter sourced transcripts in the sample with the
most primitive immunophenotype, patient sample 1.
The LMO2 intermediate promoter directs reporter gene
expression in F0 transgenic mice
To investigate the ability of the LMO2 intermediate
promoter to direct expression in vivo, lacZ reporter
Distal Promoter
Intermediate Promoter
Proximal Promoter
Empty Vector
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
 in
 s
ta
bl
e
tr
an
sf
ec
tio
n 
(ar
bit
ar
y u
nit
s)
No translocation
expressingnot expressing
0
5
10
15
25
20
0
20
40
60
80
100
120
140
Cell Lines
Ex
pr
es
si
on
 o
f L
M
O
2 
vs
.
B
-A
ct
in
 (a
rb
ita
ry
 un
its
)
FBXO3LMO2CAPRIN1
-2
0
2
4
6
8
25kb
*
*
*
centromere
telomere
Jur kat Karpas45KoptK1CcrfcemMolt4AllSil Jurkat Karpas45KoptK1CcrfcemMolt4AllSil
Translocation
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constructs were generated. Following pronuclear
microinjection, F0 transgenic mice were generated
permitting the assessment of promoter activity by
whole-mount staining of E11.5 embryos for lacZ
expression. Similar to the distal and proximal promoter
core regions (Landry et al., 2005, 2009), the intermediate
promoter on its own (IP/lacZ) does not direct any
strong tissue-speciﬁc expression (see Figure 6a for a
representative embryo). To demonstrate that the
promoter can work in combination with enhancer
elements, further constructs were generated coupling
the intermediate promoter/lacZ to proposed enhancer
elements identiﬁed in previous work (Landry et al.,
2005, 2009). In contrast with the minimal staining
pattern seen with intermediate promoter/lacZ alone,
when a proposed enhancer element immediately
adjacent to the intermediate promoter is included
in the construct (IP/lacZ/12), diffuse staining is
seen throughout the embryo (Figure 6b). Similarly,
combination of intermediate promoter/lacZ with a more
distant enhancer element 1 kb downstream of the
proximal promoter transcription start site (IP/lacZ/
þ 1) creates a striking staining pattern with reporter
gene expression directed to the tail tip, base of whiskers
and apical ectodermal ridge (Figure 6c). This distinctive
pattern mirrors the one that is seen when the same
element is combined with the proximal promoter
(Landry et al., 2009). Taken together, therefore,
comprehensive transgenic analysis has allowed us to
validate the intermediate promoter using stringent
in vivo assays as a bona ﬁde promoter element within
the LMO2 locus.
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The ETS transcription factors ERG and FLI1 bind to the
LMO2 intermediate promoter and LMO2, ERG and
FLI1 can form protein–protein complexes
The ETS family transcription factor FLI1 was recently
identiﬁed as a candidate collaborating oncogene of
LMO2 in retroviral mutagenesis models of T-ALL (Dave
et al., 2009). We therefore investigated potential interac-
tions between LMO2 and FLI1 in human T-ALL. ERG
was included in this analysis as it has been shown that
FLI1 and ERG, which is closely related to FLI1, may co-
regulate common target genes in haematopoietic stem
cells and megakaryocytes (Kruse et al., 2009) and high
ERG expression has recently been shown to predict
adverse outcome in T-ALL (Baldus et al., 2006, 2007;
Bohne et al., 2009). ChIP using antibodies to ERG and
FLI1 in Molt4 (LMO2-expressing non-translocated
human T-ALL cell line) was therefore performed. Real-
time PCR on FLI1 and ERG ChIP was then undertaken
using primer sets designed for each of the LMO2
promoters and a negative control region 98kb upstream
of the transcription start site. Speciﬁc binding of ERG
and FLI1 to the intermediate and proximal promoters
was seen (Figure 7a) with binding at the distal promoter
being only marginally above background.
Small groups of transcription factors have
been previously associated with stabilizing cellular
phenotypes, in particular when interconnected through
reciprocal interactions as seen in the fully connected
triads of OCT4/SOX2/Nanog (MacArthur et al.,
2009) and SCL/GATA2/FLI1 (Pimanda et al., 2007) in
embryonic and blood stem cells, respectively. Given the
recent report of cooperation between LMO2 and FLI1
in retroviral insertional mutagenesis models of murine
T-ALL and our identiﬁcation of FLI1 and ERG as
upstream regulators of LMO2 in human T-ALL, we
wanted to explore whether reciprocal activation of FLI1
and ERG by LMO2 might also occur in human T-ALL.
We have previously identiﬁed a þ 85 kb ERG enhancer
(Wilson et al., 2009) and þ 12 kb (Donaldson et al.,
2005) and 16 kb (Wilson et al., 2009) FLI1 enhancers
as being bound by the LMO2 partner protein SCL in
myeloid progenitor cells. We therefore undertook the
reverse experiment assessing the binding of LMO2 ChIP
material to ERG and FLI1 elements. Speciﬁc binding
of LMO2 was seen at the FLI1 promoter, þ 12 kb
and16 kb enhancers and the ERG proximal promoter
andþ 85 kb enhancer element (Figure 7b). Of note,
binding of LMO2 was also seen on the LMO2 IP and
PP promoters consistent with LMO2 autoregulation
in T-ALL.
Further biological validation of transcription factor
binding to the intermediate promoter was provided by
performing transcriptional assays. To this end, lucifer-
ase reporter constructs containing the intermediate
promoter were co-transfected with Erg, Fli1 and
LMO2 expression constructs alone or in combination
and compared with a promoter-less construct (pGL2ba-
sic). Neither ERG nor LMO2 alone showed signiﬁcant
activation of the promoter, yet co-transfection of both
resulted in a near twofold activation. FLI1 alone
showed twofold activation and again this could be
enhanced further by co-transfection with LMO2
(Figure 7c). These experiments therefore show that
LMO2, ERG and FLI1 not only bind to the
Ip/LacZ Ip/LacZ/+1Ip/LacZ/-12
Promoters
Enhancers
LMO2
10kb
LacZ LacZ LacZ
Figure 6 In vivo validation of promoter/LacZ and promoter–enhancer/LacZ F0 transgenic mice. F0 transgenic mice were generated
by pronuclear microinjection with promoter and promoter–enhancer-coupled LacZ constructs. Speciﬁc staining patterns are seen in the
promoter–enhancer/LacZ embryos. (a) Ip/LacZ: one of seven embryos stained; (b) Ip/LacZ/12: three of eleven embryos stained;
(c) Ip/LacZ/þ 1: two of six embryos stained.
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intermediate promoter, but also have the capacity to
enhance its activity. To investigate whether the syner-
gistic transactivation was paralleled by protein–protein
interactions, co-immunoprecipitation assays were per-
formed using a haemagglutinin (HA)-tagged LMO2
expression vector, a myc-tagged FLI1 expression vector
and an untagged ERG expression vector. These were
tranfected alone or in combination and proteins bound
to LMO2 immunoprecipitated with an anti-HA anti-
body to conﬁrm the association of LMO2 and ERG and
of LMO2 and FLI1 proteins (Figure 7d). Taken
together, these experiments not only show that LMO2,
ERG and FLI1 proteins bind to the intermediate
promoter, but also that this binding likely has a role
in synergistic activation of this promoter.
LMO2/ERG/FLI1 function upstream of HHEX/PRH
that is required for the growth of T-ALL cell lines
Following the recent identiﬁcation of hhex/prh as a
mediator of lmo2-induced thymocyte self-renewal
during both the latency and leukaemic phases of
lmo2-based mouse models of T-ALL (McCormack
et al., 2010), we also investigated whether the potentially
self-sustaining triad of LMO2/ERG/FLI1 might directly
regulate HHEX/PRH expression. We had previously
identiﬁed an enhancer in the ﬁrst intron of HHEX/PRH
(þ 1 kb enhancer) (Donaldson et al., 2005) and now
show that indeed this element is strongly bound by
LMO2, FLI1 and ERG in T-ALL cells (Figure 7e).
Further validation of this binding to the HHEXþ 1
enhancer was conﬁrmed by transactivation experiments
using an sv HHEXþ 1 luciferase reporter construct
co-transfected with ERG, FLI1 and LMO2 expression
constructs alone or in combination. By comparison with
the empty control vector, both the combination of
LMO2 and ERG, the combination of LMO2 and FLI1
and the combination of LMO2, ERG and FLI1 has
higher activity than the addition of LMO2, ERG or
FLI1 alone (Figure 7f). Transactivation studies thus
demonstrated that LMO2, FLI1 and ERG not only bind
to the HHEXþ 1 element but also have the capacity to
enhance its activity.
The previous studies identifying HHEX/PRH as a
mediator of the leukaemogenic phenotype of Lmo2-
induced mouse models of T-ALL did not address
whether there was a direct link between Lmo2 and
HHEX/PRH. Having established that there is indeed a
direct link, we next asked whether HHEX/PRH was
important for the growth of human T-ALL cells. Using
vectors previously established to produce effective
knockdown of HHEX/PRH (Noy et al., 2010) we now
show that following expression of short hairpin RNA
against HHEX/PRH in the LMO2-expressing non-
translocated cell line Molt4, cells were unable to grow,
whereas cells transfected with a control vector could
expand as expected (Figure 7g). Taken together, these
results not only support the existence of a highly
connected LMO2, FLI1, ERG triad in T-ALL but also
Figure 7 LMO2, ERG, FLI1 and HHEX/PRH form a subcircuit of T-ALL transcriptional programmes. (a) Real-time PCR in Molt4
FLI1 and ERG ChIP material. Real-time PCR demonstrates the binding to the three promoters of LMO2 in Molt4 chromatin
subjected to immunoprecipitation with FLI1 and ERG antibodies with the highest amount of binding to the intermediate promoter.
Bars represent mean enrichment relative to IgG and a negative control region, and error bars represent the s.d. of replicates. Data are
representative of two replicates of experiments designed with duplicate data points. (b) Real-time PCR in Molt4 LMO2 ChIP material.
Real-time PCR demonstrates binding to the LMO2 promoters, ERG and FLI1 promoters and enhancer element in Molt4 chromatin
subjected to immunoprecipitation with LMO2 antibody. Results show binding of LMO2 to each of the LMO2 promoters, to the FLI1
enhancer elements and to the ERG promoters and enhancer element. Signiﬁcantly, there is a moderate degree of binding to the LMO2
intermediate promoter, suggesting a role of LMO2 autoregulation via this element in those T-ALL samples lacking LMO2
translocations. Bars represent mean enrichment relative to IgG and a negative control region, and error bars represent s.d. of
replicates. Data are representative of two replicates of experiments designed with duplicate data points. (c) Transactivation assays of
the intermediate promoter with LMO2, ERG and FLI1 alone and in combination. Intermediate promoter luciferase construct was co-
transfected with Erg, Fli1 and LMO2 expression constructs alone or in combination and compared with a parallel experiment with
control vector. Combination of LMO2/ERG and LMO2/Fli1 has higher activity than the addition of single factors. Data shown
represent intermediate promoter activity normalized for cell number and transfection efﬁciency and further normalized against the
equivalent combination of expression vectors with the empty vector, pGL2basic. Four biological replicates each of three technical
replicates were performed. (d) Co-immunoprecipitation of ERG and FLI1 with LMO2. Co-immunoprecipitation assays were
performed using an HA-tagged LMO2 expression vector, a myc-tagged Fli1 expression vector and an untagged ERG expression vector
tranfected alone or in combination. Control lanes were loaded with native whole-cell extract of HA-LMO2/ERG or HA-LMO2/myc-
FLI1 transfected cells and demonstrate high levels of target protein production in these cells. No ERG or FLI1 protein is detected in
the IP samples transfected with HA-LMO2 ERG or FLI1 alone. However, ERG or FLI1 protein is clearly detectable in cells
transfected with HA-LMO2 in combination with ERG/FLI1, thus conﬁrming the association of LMO2 and ERG and of LMO2 and
Fli1 proteins. Western blot images are cropped to remove IgG bands. (e) Real-time PCR in Molt4 ERG, FLI1 and LMO2 ChIP
material. Real-time PCR demonstrates binding to the Hhexþ 1 enhancer element in Molt4 chromatin subjected to immunoprecipita-
tion with ERG, FLI1 and LMO2 antibody. Bars represent mean enrichment relative to IgG and a negative control region, and error
bars represent s.d. of replicates. (f) Transactivation assays of the Hhexþ 1 enhancer with LMO2, ERG, FLI1 alone and in
combination. The minimal promoter sv Hhexþ 1 enhancer luciferase construct was co-transfected with Erg, Fli1 and LMO2
expression constructs alone or in combination and compared with a parallel experiment with sv luciferase. Both the combination of
LMO2/ERG and LMO2/Fli1 has higher activity than the addition of just the single Ets factor and the combination of all three has the
highest activity. Data shown represent activity on sv Hhexþ 1 normalized for cell number and transfection efﬁciency and further
normalized against the equivalent combination of expression vectors with the empty vector, sv-luciferase. Four biological replicates
each of three technical replicates were performed. (g) Knockdown of HHEX/PRH. The Lmo2-expressing T-ALL cell line Molt4 was
transfected using vectors previously established to produce effective knockdown of Hhex. HHEX short hairpin RNA (shRNA) cells
were unable to grow, while those transfected with a control vector expanded as expected following the initial loss of cells due to
puromycin selection. At least six independent knockdown experiments were performed with each construct(s). (h) Representation of
FLI1–ERG–LMO2–HHEX/PRH recursively wired circuit.
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demonstrate that HHEX is a direct target of this triad
with a likely role in human T-ALL (Figure 7h).
Discussion
Understanding the molecular mechanisms controlling
the expression of LMO2 is likely to provide new insights
into the pathogenesis of T-cell leukaemias and will
also provide valuable information with regard to the
transcriptional control of hematopoietic and endothelial
development. Here, we have used ChIP-on-chip in
patient T-ALL material to highlight the central nature
of promoter usage in TALL and also to the discovery of
a previously unrecognized third promoter of LMO2.
This novel promoter functions both in vitro and in vivo
and participates in a recursively wired regulatory loop
together with the ETS factors FLI1 and ERG. More-
over, all three members of this triad bind to an enhancer
of the HHEX/PRH homeobox transcription factor gene
thus linking a potentially self-sustaining regulatory
circuit with expression of a recently identiﬁed candidate
downstream mediator of LMO2-induced T-ALL.
It has long been noted that genes critical for blood
and endothelial development contain functional ETS-
binding sites, and using a combination of approaches,
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expression of numerous ETS factors, including FLI1,
SPI1/PU.1, ELF1and ETS1, has been shown to control
the expression of SCL/TAL1 (Gottgens et al., 2004),
LYL1 (Chan et al., 2007), LMO2 (Landry et al., 2005)
and GATA2 (Pimanda et al., 2007). What has been less
well studied, however, is how dysregulation of this same
constellation of genes might facilitate leukaemogenesis.
Ectopic or aberrant expression of genes in leukaemia is
an important and as yet relatively unexplored ﬁeld.
Indeed ectopic expression of stem cell-afﬁliated genes in
the absence of translocation suggests that these cells
may re-invoke some aspects of transcriptional control
mechanisms normally used in more primitive cells.
Recent work from insertional mutagenesis models in
mice (Dave et al., 2009) has shown that the genes and
signalling pathways deregulated in murine leukaemias
with retroviral insertions at LMO2 are analogous to
both those dysregulated in highly LMO2-expressing
human leukaemias (Ferrando et al., 2002; Yeoh et al.,
2002; Chiaretti et al., 2004) and to the LMO2 retro-
viral insertion-mediated leukaemias induced in severe
combined immunodeﬁciency-X1 patients (Hacein-Bey-
Abina et al., 2003a, b, 2008). Moreover, many of these
genes are components of haematopoietic stem cell
transcriptional regulatory networks.
Cell-fate mapping in CD2-lmo2 transgenic mice
(McCormack et al., 2010) has shown that the leukae-
mia-initiating cell is established within the thymus many
months before the development of leukaemia. In
contrast with wild type, transgenic thymic cells were
able to self-renew and to provide robust stable engraft-
ment in primary, secondary, tertiary and quaternary
recipients. Taken together, these data suggest that
thymocyte self-renewal may have been reactivated by
lmo2. Expression proﬁling of pre-leukaemic and wild-
type thymocytes, and human T-ALL samples identiﬁed
a gene-expression signature containing candidates with
known roles in haematopoietic stem cell function, and a
bone marrow reconstitution model showed that HHEX/
PRH overexpression recapitulated the oncogenic
potential of lmo2.
Dave et al. (2009) and McCormack et al. (2010) both
suggest a possible role of the LMO2-ETS factor
interaction and identify HHEX/PRH as a potential
downstream collaborator in mice. However, although
these studies have identiﬁed lmo2, the ETS factors and
HHEX/PRH as collaborating oncogenes, they do not
distinguish whether they function in a parallel, over-
lapping or hierarchical manner. We now present data
showing that LMO2-ETS factors collaborate in T-ALL
and that these directly interact with the HHEX þ 1
enhancer, the ﬁrst time HHEX/PRH has been impli-
cated in human T-ALL. A possible mechanism for these
leukaemias may therefore be a failure to downregulate
members of the LMO2-ERG-FLI1 triad identiﬁed in the
current study. The molecular mechanisms responsible
for downregulation of intermediate promoter activity
are not known even though preliminary observation
demonstrates that its activity is highly sensitive to the
negative regulatory region upstream of the distal
promoter (Go¨ttgens B, unpublished observation).
Nevertheless, identiﬁcation of upstream regulators
responsible for ectopic expression of LMO2 represents
an important milestone in furthering our understanding
of aberrant transcriptional programmes in T-ALL.
Our approach to identiﬁcation of critical elements is
in no way T-ALL or LMO2 speciﬁc and may be
considered generally applicable to other genes ectopi-
cally expressed in other malignancies. It has been
previously shown possible to inhibit ETS factors in
whole animal models without any harm coming to
normal tissue (Huang et al., 2006). As high LMO2
removal is sufﬁcient to cause death of leukaemic cells
even after acquisition of secondary genetic abnormal-
ities (Appert et al., 2009), identiﬁcation of the molecular
mechanisms involved in aberrant ectopic expression of
LMO2 may open up new targeted therapeutic options
directed towards the impediment of upstream regulators
to block the maintenance of the leukaemia phenotype.
Materials and methods
Cell preparation and culture
Preparation of cell samples and patient information such as
translocation status and immunophenotype is provided in
Supplementary Materials.
Chromatin immunoprecipitation
ChIP was carried out as previously described (Wilson et al.,
2009) using 2 105 (primary samples) and 1 107 (cell lines) as
per the condition using commercially available antibodies
(Supplementary Information). The relative enrichment of
immunoprecipitated DNA was estimated using real-time
PCR as described in Supplementary Information). ChIP-chip
assays were performed as described (Follows et al., 2006). For
details on transcription factor ChIP assays, see Supplementary
Information.
RNA analysis
RNA was prepared from patient samples and cell lines with
TRIZOL reagent (Invitrogen, Paisley, UK) and was DNAase
treated to eliminate residual genomic DNA using TURBOD-
NAse (Ambion, Huntingdon, UK). cDNA was prepared using
random hexamers and TaqMan reverse transcriptase reagents
kit (Applied Biosystems, Foster City, CA, USA). The
procedure for quantitation of transcripts derived from each
of the three promoters by quantitative real-time PCR is
provided in Supplementary Information.
Quantitative PCRs (qPCR) were undertaken using Strata-
gene Brilliant Sybr Green QPCR Master Mix (Agilent
Technologies, Stockport, UK). Standard curves for LMO2
and b-actin were created using dilutions of linearized plasmid
templates.
Luciferase reporter assay and transgenic mouse analysis
The known promoters and candidate new promoter and
enhancer regions were PCR ampliﬁed from human genomic
DNA and subcloned into a luciferase reporter vector. Cells
were transfected, subjected to antibiotic selection at an
appropriate dose, lysate prepared and assayed as previously
described (Landry et al., 2009). The promoter and enhancer
regions were PCR ampliﬁed from human genomic DNA and
subcloned into a lacZ reporter vector. Transgenic mice were
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generated as previously described (Landry et al., 2009), and
activity of the intermediate promoter and enhancers was
assessed by whole-mount staining of E11.5 embryos for LacZ
activity.
Co-immunprecipitation
293T cells were transiently transfected with HA-tagged LMO2,
untagged ERG and myc-tagged FLI1 expression constructs
alone and in combination and co-immunoprecipation assays
performed following standard protocols using anti-HA
antibody (Santa Cruz Biotechnology, Heidelberg, Germany,
sc805G), Erg antibody (Santa Cruz, sc-354 ) or c-myc
antibody (Santa Cruz, sc-40).
Knockdown of HHEX/PRH
A total of 5 106 Molt4 cells were electroporated using 10 mg
green ﬂuorescent protein short hairpin RNA (control) or 5 mg
PRH49 and 5mg PRH51 short hairpin RNA plasmids in
combination previously as described (Noy et al., 2010). Cells
were selected with 1mg/ml puromycin and viable cells were
counted daily for 14 days. At least six independent knockdown
experiments were performed with each construct(s).
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